
At ASCO, Merck KGaA Shows How Its Drug Measures Up as Treatment for Rare Type of Tumor
Merck KGaA’s pimicotinib led to statistically significant improvement on multiple measures of its Phase 3…
Merck KGaA’s pimicotinib led to statistically significant improvement on multiple measures of its Phase 3 test in tenosynovial giant cell tumor, positioning the drug to potentially compete with medications from Daiichi Sankyo and Ono Pharma. The Phase 3 results were presented during the annual meeting of the American Society of Clinical Oncology. The post At…
UnitedHealth Group has had a difficult year marked by a dramatic stock drop, leadership shake-up and mounting regulatory scrutiny. Experts point to its aggressive Medicare Advantage strategy and a rapidly evolving healthcare landscape as key drivers of its challenges. The post Analysis: The No Good, Very Bad Year for UnitedHealth appeared first on MedCity News.
What if the kind of cuts we should be talking about are the ones that actually make care better? Like cutting confusion. Because for many people, the biggest barrier to healthcare access isn’t cost or availability – it’s complexity. The post A Call for Healthcare Cuts — But Not the Kind You’re Thinking Of appeared…
This is a great opportunity to align your strategies with CMS’s evolving framework by refining care models to focus on impact, investing in digital capabilities that support data use, and continuing to build infrastructure that addresses disparities in care. The post CMS’s Final Rule Impacting Star Ratings Puts Outcomes In Focus — Are Health Plans…
Céline Gounder, KFF Health News’ editor-at-large for public health, discussed covid-19 vaccines and prostate cancer on WAMU’s “1A” on May 27. Click here to hear Gounder on “1A.” Senior correspondent Sarah Jane Tribble discussed how internet dead zones deepen chronic health issues in rural communities on The Commonwealth Fund’s “The Dose” on May 23. Click…
Astellas Pharma gets global rights to an Evopoint Biosciences antibody drug conjugate that targets Claudin 18.2. Last year, Astellas’s antibody drug Vyloy became the first FDA-approved therapy for this target. The post Astellas Stays Competitive in Hot Gut Cancer Target, Paying $130M to License Evopoint Drug appeared first on MedCity News.
A list of interesting articles to checkout as you head to the weekend. How America Built the World’s Most Successful Market for Generic Drugs.Reference Pricing as a Deterrent to Entry.Will Florida Medicaid cover a hospitalization in South Dakota?Will better data rescue value-based care?The return of COVID?
Health tech companies made several major funding announcements in May. Here is a list of some of the biggest funding rounds. The post 4 Notable Health Tech Funding Announcements in May appeared first on MedCity News.
May has seen a slew of executive hires, exits and layoffs across the healthcare industry. For example, the American Medical Association and TigerConnect named new CEOs, and Google and UnitedHealth Group have seen key executives leave their roles. There were also layoffs at organizations including Devoted Health and New York-Presbyterian. The post Healthcare Moves: A…
In this episode, we’re joined by Margaret Malone, principal of Flare Capital Partners. She discusses the investment trends she’s following in the women’s health space and advice she has for startups. The post MedCity FemFwd: Investment Trends In Women’s Health appeared first on MedCity News.